Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB/II Study of Fruquintinib Combined With Capecitabine in the First-line Maintenance Treatment of RAS/BRAF Wild-type Metastatic Colorectal Cancer

Next Previous
Trial Profile

A Phase IB/II Study of Fruquintinib Combined With Capecitabine in the First-line Maintenance Treatment of RAS/BRAF Wild-type Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Fruquintinib (Primary) ; Cetuximab
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 30 Apr 2025 Results(n=16) preliminary results showed that the efficacy of F combined with C is promising with well tolerance as MT in RAS/BRAF wild-type mCRC were presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 16 Oct 2023 According to a HUTCHMED media release, new and updated clinical data from this study will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain
  • 04 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top